Tissue-free versus tissue-reliant ctDNA testing in solid tumors

John Paul Shen, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, compares recent methylation-based tissue free testing to traditional tissue-dependent circulating tumor (ctDNA) approaches. With the ongoing consensus that sensitivity changes based on metastatic location and somatic mutations of the tumour, further trials are necessary to confirm how this new method will differ in specificity and sensitivity in detecting molecular residual disease in circulating tumour DNA. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео Tissue-free versus tissue-reliant ctDNA testing in solid tumors канала VJOncology